The EFNA5 Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered from the Huh-7 human hepatocellular carcinoma cell line, featuring targeted disruption of the EFNA5 gene (encoding ephrin-A5) in Homo sapiens. This polyclonal pool comprises a heterogeneous collection of cells harboring diverse EFNA5 loss-of-function mutations, offering a versatile tool for investigating ephrin-A5-dependent signaling without clonal artifacts. The product is designed for stable loss-of-function studies, enabling researchers to examine the consequences of EFNA5 ablation in a liver cancer background.
The Huh-7 host cell line is a well-differentiated hepatocellular carcinoma model originally derived from a liver tumor of a 57-year-old Japanese male. These cells are widely employed in liver cancer research, drug metabolism studies, and as a host for hepatitis C virus (HCV) replication, providing a clinically relevant platform for studying hepatic tumor biology. Their robust growth characteristics and well-characterized signaling networks make them an ideal recipient for gene-editing approaches focused on oncogenic pathways.
EFNA5 encodes ephrin-A5, a GPI-anchored ligand that engages Eph receptor tyrosine kinases to initiate bidirectional signaling. Forward signaling via Eph receptors activates SRC kinase, focal adhesion kinase (PTK2/FAK), and RHOA/RAC1 GTPases, driving cytoskeletal remodeling and adhesion modulation. Reverse signaling involves adaptors such as Grb4 and Nck2. Transcription of EFNA5 is regulated by TP53, NF-??B, Wnt/??-catenin, and HIF-1??, while protein shedding is mediated by ADAM10 and ADAM17. Key downstream pathways include Ras-MAPK (ERK1/2) and PI3K-AKT, which influence proliferation and motility.
In Huh-7 hepatocellular carcinoma cells, EFNA5 disruption impairs the ephrin-A5/Eph axis, potentially attenuating tumor cell migration and invasion. The loss of ephrin-A5-mediated repulsive cues and altered focal adhesion turnover??driven by dampened SRC and FAK activation??disrupts the actin cytoskeleton dynamics crucial for metastatic dissemination. This knockout model enables dissection of ephrin-A5??s tumor-promoting or -suppressing roles in liver cancer, particularly in the context of cell adhesion, epithelial-mesenchymal transition, and crosstalk with growth factor pathways.
Researchers can employ this polyclonal knockout population to investigate ephrin/Eph signaling in hepatocellular carcinoma. Typical assays include Transwell migration and invasion assays to quantify metastatic potential, Western blotting for phosphorylated EphA4, SRC, and FAK, and immunofluorescence for F-actin and paxillin. Co-immunoprecipitation of EphA4 complexes, phospho-kinase arrays, and apoptosis or cell adhesion assays further expand its utility. The model is well-suited for anti-metastatic drug screening. For further information or technical support, please contact Ascent Research.
